My Portfolio
My Watchlists
Profile & Performance
Smart Portfolio
Find & Follow Experts
Top Lists
Top Experts
Make Better, Data Driven Investment Decisions
TipRanks tools are all you need to make data-driven investment decisions, conduct comprehensive stock research, find new investment ideas, analyze your portfolio, and follow the best-performing Wall Street experts.
About Us
Plans & Pricing
Incyte Corp (INCY)
NASDAQ:INCY

Incyte Stock Analysis & Ratings

Incyte Stock Analysis Overview

Smart Score
9
Outperform
1
2
3
4
5
6
7
8
9
10
Learn more about TipRanks Smart Score
The Incyte stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.

Stock Chart

INCY

INCY Stock Stats

Previous Close$67.72
Open$68
Bid64 x 100
Ask76.81 x 100
Today’s Range$64.69 - $69.62
52-Week Range$61.91 - $101.47
Volume3.74M
Average Volume1.67M
Market Cap$14.35B
Beta0.72
P/E Ratio28.0
EPS2.42
Earnings DateFeb 17, 2022

Company Description

Incyte Corp

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib), and ICLUSIG (ponatinib). The company was founded by Roy A. Whitfield in April 1991 and is headquartered in Wilmington, DE.
Sector
Healthcare
Industry
Biotechnology
CEO
Herve Hoppenot
Employees
1,773
ISIN
US45337C1027
Address
1801 Augustine Cut-Off, Wilmington, DE, 19803, US

Financials


P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

INCY FAQ

What was Incyte’s price range in the past 12 months?
Incyte lowest stock price was $61.91 and its highest was $101.47 in the past 12 months.
    What is Incyte’s market cap?
    Incyte’s market cap is $14.35B.
      What is Incyte’s price target?
      The average price target for Incyte is $93.69. This is based on 15 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $136.00 ,the lowest forecast is $75.00. The average price target represents 44.23% Increase from the current price of $64.96.
        What do analysts say about Incyte?
        Incyte’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 15 Wall Streets Analysts.
          When is Incyte’s upcoming earnings report date?
          Incyte’s upcoming earnings report date is Feb 17, 2022 which is in 77 days.
            How were Incyte’s earnings last quarter?
            Incyte released its earnings results on Nov 02, 2021. The company reported $0.82 earnings per share for the quarter, beating the consensus estimate of $0.582 by $0.238.
              Is Incyte overvalued?
              According to Wall Street analysts Incyte’s price is currently Undervalued.
                Does Incyte pay dividends?
                Incyte does not currently pay dividends.
                What is Incyte’s EPS estimate?
                Incyte’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does Incyte have?
                Incyte has 220,890,000 shares outstanding.
                  What happened to Incyte’s price movement after its last earnings report?
                  Incyte reported an EPS of $0.82 in its last earnings report, beating expectations of $0.582. Following the earnings report the stock price went down -3.691%.
                    Which hedge fund is a major shareholder of Incyte?
                    Among the largest hedge funds holding Incyte’s share is Dodge & Cox. It holds Incyte’s shares valued at 1B.

                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis